Blue Capital Inc. Purchases Shares of 9,043 Stryker Co. (NYSE:SYK)

Blue Capital Inc. acquired a new stake in Stryker Co. (NYSE:SYK - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 9,043 shares of the medical technology company's stock, valued at approximately $3,256,000. Stryker comprises approximately 2.3% of Blue Capital Inc.'s investment portfolio, making the stock its 14th largest position.

A number of other hedge funds have also bought and sold shares of the company. Kohmann Bosshard Financial Services LLC bought a new position in Stryker in the fourth quarter worth about $25,000. Rakuten Securities Inc. boosted its position in Stryker by 618.2% in the fourth quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company's stock valued at $28,000 after buying an additional 68 shares during the last quarter. Centricity Wealth Management LLC purchased a new position in shares of Stryker during the fourth quarter worth $30,000. BankPlus Trust Department acquired a new stake in Stryker during the fourth quarter worth about $33,000. Finally, VSM Wealth Advisory LLC acquired a new stake in shares of Stryker during the 4th quarter worth approximately $36,000. Institutional investors own 77.09% of the company's stock.

Insider Buying and Selling

In other Stryker news, Director Allan C. Golston sold 2,458 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the transaction, the director now owns 14,895 shares in the company, valued at $5,705,827.65. This trade represents a 14.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Ronda E. Stryker sold 200,000 shares of Stryker stock in a transaction dated Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total value of $75,392,000.00. Following the completion of the transaction, the director now owns 3,417,326 shares in the company, valued at $1,288,195,208.96. The trade was a 5.53 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 5.90% of the company's stock.

Stryker Stock Performance

SYK traded down $1.38 during trading on Thursday, reaching $382.68. 926,986 shares of the company were exchanged, compared to its average volume of 1,356,702. The stock has a market cap of $146.06 billion, a P/E ratio of 49.31, a PEG ratio of 2.93 and a beta of 0.93. The firm has a 50 day moving average of $365.90 and a 200 day moving average of $374.10. Stryker Co. has a 52 week low of $314.93 and a 52 week high of $406.19. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical technology company reported $2.84 earnings per share for the quarter, topping analysts' consensus estimates of $2.73 by $0.11. The company had revenue of $5.87 billion during the quarter, compared to analyst estimates of $5.68 billion. Stryker had a net margin of 13.25% and a return on equity of 23.58%. The business's revenue for the quarter was up 11.9% compared to the same quarter last year. During the same period in the prior year, the business posted $2.50 EPS. On average, sell-side analysts forecast that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Monday, June 30th will be paid a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.88%. Stryker's dividend payout ratio is presently 45.41%.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on SYK. JPMorgan Chase & Co. increased their price target on Stryker from $420.00 to $445.00 and gave the stock an "overweight" rating in a research report on Wednesday, January 29th. Argus set a $450.00 price objective on Stryker in a research note on Monday, February 3rd. Barclays lifted their price target on shares of Stryker from $418.00 to $443.00 and gave the company an "overweight" rating in a research report on Monday, February 10th. Evercore ISI lowered their target price on shares of Stryker from $400.00 to $390.00 and set an "outperform" rating for the company in a research note on Friday, May 2nd. Finally, StockNews.com lowered Stryker from a "buy" rating to a "hold" rating in a research note on Thursday, March 6th. Five research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $427.05.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.